Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Up 136.0% in December

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 547,500 shares, a growth of 136.0% from the December 15th total of 232,000 shares. Currently, 2.7% of the shares of the company are sold short. Based on an average trading volume of 322,600 shares, the short-interest ratio is currently 1.7 days.

Institutional Trading of Aadi Bioscience

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd acquired a new position in Aadi Bioscience during the 3rd quarter worth $32,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Aadi Bioscience during the second quarter valued at about $37,000. Finally, BML Capital Management LLC acquired a new stake in Aadi Bioscience in the third quarter worth about $4,120,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Stock Up 8.4 %

AADI stock opened at $3.24 on Thursday. The stock has a market cap of $79.86 million, a PE ratio of -1.42 and a beta of 0.65. The firm’s 50-day simple moving average is $2.65 and its 200 day simple moving average is $2.05. Aadi Bioscience has a fifty-two week low of $1.21 and a fifty-two week high of $3.81.

Aadi Bioscience (NASDAQ:AADI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.46) EPS for the quarter, meeting the consensus estimate of ($0.46). The company had revenue of $7.21 million for the quarter, compared to analyst estimates of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same quarter last year, the business earned ($0.60) earnings per share. Equities analysts forecast that Aadi Bioscience will post -1.78 EPS for the current fiscal year.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.